Indication
Mirabegron Pharmacokinetics
1 clinical trial
2 products
Clinical trial
A Phase 3, Double-blind, Randomized, Multicenter, Parallel Group, Placebo-controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Subjects From 5 to < 18 Years of Age With Overactive BladderStatus: Terminated, Estimated PCD: 2023-07-07
Product
PlaceboProduct
Mirabegron